CLINICAL TRIALS PROFILE FOR NEUPRO
✉ Email this page to a colleague
All Clinical Trials for NEUPRO
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00292227 ↗ | Cardiac Effects of Rotigotine Transdermal System in Subjects With Advanced-stage Idiopathic Parkinson's Disease | Completed | UCB Pharma | Phase 1 | 2006-01-01 | The purpose of this trial is to assess whether rotigotine has an effect on the electrical activity of the heart. Moxifloxacin infusion is used as positive control to assess assay sensitivity. |
| NCT00296192 ↗ | Efficacy, Safety and Tolerability of Rotigotine Nasal Spray for the Acute Treatment of Parkinson Symptoms | Completed | UCB Pharma | Phase 2 | 2006-02-01 | The objective of this trial is to evaluate safety and efficacy of rotigotine nasal spray (SPM 952) in a single dose application scheme. Subjects will undergo a 2 - 28 days screening period in which eligibility criteria will be checked. Subjects will then be hospitalized for one night. In the morning of the next day, subjects will be randomly assigned either to rotigotine or placebo nasal spray and will then receive a single dose of trial medication. Safety assessments after application include adverse events, 12-lead electrocardiograms, blood pressure and heart rate assessments, and laboratory checks. Efficacy will be assessed by application of motor examination scores. The first subject is planned to be enrolled in February 2006. The last subject is planned to be enrolled in May 2006. Last subject out is expected for August 2006. |
| NCT00464737 ↗ | The Use of Rotigotine for Treatment of Reducing Signs and Symptoms of Fibromyalgia in Adults. | Completed | UCB Pharma | Phase 2 | 2007-03-01 | This trial is to investigate the efficacy and safety of rotigotine as compared to placebo in reducing signs and symptoms of fibromyalgia syndrome. The effects of rotigotine on pain, sleep, general activity, mood, and quality of life, and the use of rescue medication to treat pain will be assessed. |
| NCT00474058 ↗ | Randomized Evaluation of the 24-Hour Coverage: Efficacy of Rotigotine | Completed | UCB Pharma | Phase 3 | 2007-05-01 | The objective of this trial is to assess the effects of transdermal rotigotine on the control of early morning motor function and sleep disorders compared to placebo in subjects with idiopathic Parkinsons´s disease. In addition, effects of rotigotine on specific nocturnal and non-motor symptoms of Parkinson´s disease will be evaluated. |
| NCT00505687 ↗ | An Open-Label Extension Trial to Assess the Safety and Tolerability of Long Term Treatment of Rotigotine in Subjects With Idiopathic Parkinson's Disease | Completed | UCB Pharma | Phase 3 | 2005-02-01 | The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of rotigotine in subjects with idiopathic PD. |
| NCT00522379 ↗ | Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch | Completed | UCB Pharma | Phase 3 | 2007-07-01 | The purpose of this study is to show Rotigotine dose response at four doses of Rotigotine used with L-dopa in treating advanced stage Parkinson's disease. |
| NCT00593606 ↗ | Safety and Tolerability Trial of Switching From Ropinirole to Rotigotine | Completed | UCB Pharma | Phase 3 | 2007-07-01 | This is a Phase 3b, open-label, multicenter trial to assess the safety and tolerability of switching from ropinirole therapy to the rotigotine transdermal system and its effect on symptoms in subjects with idiopathic Parkinson's disease |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for NEUPRO
Condition Name
Clinical Trial Locations for NEUPRO
Trials by Country
Clinical Trial Progress for NEUPRO
Clinical Trial Phase
Clinical Trial Sponsors for NEUPRO
Sponsor Name
